BDBM50101769 (S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylcarbamoyl)-ethyl]-thiophene-2-carbonyl}-amino)-propionic acid::CHEMBL292241

SMILES CC(C)(C)c1ccc(cc1)S(=O)(=O)N[C@@H](CNC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)C(O)=O

InChI Key InChIKey=XLYGKRZQPDXMEM-UHFFFAOYSA-N

Data  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 50101769   

TargetIntegrin alpha-IIb/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)
Affinity DataIC50: 65nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta-3 integrin by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)
Affinity DataIC50: 12nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor (Vn/293) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed